Patent intelligence · US
US 8957033
Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
Patent details — US 8957033
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 17, 2015
- Expiration
- Feb 12, 2035
- Claims
- 23
- CPC classes
- A61K, A61K31/351, A61K31/70, A61K45/06
Quick answer
US 8957033 (Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof) is held by Beijing Prelude Pharm. SCI. & Tech. Co., Ltd.. Status: granted. Granted Feb 17, 2015. Expires Feb 12, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 23
- CPC classes
- A61K, A61K31/351, A61K31/70, A61K45/06, A61K9/0019, A61K9/1623
More from Beijing Prelude Pharm. SCI. & Tech. Co., Ltd.
Related pharmaceutical patents in our USPTO index.
-
US 12414953
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
granted -
US 12129262
CDK inhibitors and their use as pharmaceuticals
granted -
US 11939340
CDK inhibitors and their use as pharmaceuticals
granted -
US 11702423
BRM targeting compounds and associated methods of use
granted -
US 11685744
CDK inhibitors and their use as pharmaceuticals
granted -
US 11673893
CDK inhibitors and their use as pharmaceuticals
granted -
US 11622970
BCL-2 inhibitors and their use as pharmaceuticals
granted -
US 11524962
Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)
granted
Frequently asked questions
What is US patent 8957033?
US 8957033 (Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof) is held by Beijing Prelude Pharm. SCI. & Tech. Co., Ltd.. Status: granted. Granted Feb 17, 2015. Expires Feb 12, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8957033?
Beijing Prelude Pharm. SCI. & Tech. Co., Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 16 pharmaceutical patents for this assignee.
When does US 8957033 expire?
Our index shows an expiration date of Feb 12, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.